CHARACTERIZATION OF THE INTERACTION OF THE CERVANE ALKALOID, IMPERIALINE, AT MUSCARINIC RECEPTORS INVITRO

被引:24
作者
EGLEN, RM
HARRIS, GC
COX, H
SULLIVAN, AO
STEFANICH, E
WHITING, RL
机构
[1] Institute of Pharmacology, Syntex Research, Palo Alto, California, 94304
关键词
IMPERIALINE; MUSCARINIC RECEPTOR SUBTYPES; CERVANE ALKALOIDS;
D O I
10.1007/BF00165295
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The action of the cervane alkaloid, imperialine, has been assessed at M1, M2 and M3 receptors in functional assays and at M1, M2, M3 and putative M4 sites in binding studies. In functional studies, imperialine acted as a selective surmountable antagonist at M2 receptors in guinea-pig isolated atria and uterus (-log K(B) = 7.7 and 7.4, respectively), in comparison to M1 receptors in canine isolated saphenous vein (-log K(B) = 6.9) or M3 receptors in a range of guinea-pig isolated smooth muscles including ileum, trachea, fundus, seminal vesicle or oesophagus (-log K(B) = 6.6-6.8). In rat aorta, the -log K(B) value at the M3 receptor (5.9) was slightly, but significantly, lower. In competition radioligand binding studies, imperialine was also selective toward to M2 sites in rat myocardium (-log K(i) = 7.2) with respect to M1 and M3 sites (rat cerebral cortex, rat submaxillary gland; -log K(i) = 6.1 and 5.7, respectively). However, it did not significantly discriminate between rat cardiac M2 sites and putative M4 sites in rabbit lung (-log K(i) = 6.9). Imperialine resembles the alkaloid himbacine in terms of its pharmacological profile at muscarinic receptor subtypes in that it acts as an M2 selective antagonist with respect to M1 or M3 sites. It may also provide a second, commercially available, antagonist with which to discriminate between M1 and M4 receptors.
引用
收藏
页码:144 / 151
页数:8
相关论文
共 42 条
[41]   UPTAKE OF ATROPINE AND RELATED DRUGS BY INTESTINAL SMOOTH MUSCLE OF GUINEA-PIG IN RELATION TO ACETYLCHOLINE RECEPTORS [J].
PATON, WDM ;
RANG, HP .
PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES, 1965, 163 (990) :1-+
[42]  
SHARIF SI, 1990, N-S ARCH PHARMACOL, V341, P425